Shopping Cart 0
Cart Subtotal
USD 0

Magenta Therapeutics Inc (MGTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Magenta Therapeutics Inc (Magenta Therapeutics) formerly HSCTCo Therapeutics Inc, is a clinical-stage biotechnology company focused on developing novel medicines which revolutionizes bone marrow transplant for treating autoimmune diseases, blood cancers and rare genetic diseases. Its product candidates include C100, C200, and C300 which are targeted antibody-drug conjugates used for transplant conditioning methods to reduce hematopoietic stem cells (HSCs) and immune cells in bone marrow; MGTA-M100, for mobilization of hematopoietic stem cells (HSCs); MGTA-456, an allogeneic stem cell therapy that allows expansion of cord blood stem cells; and G100, targeting graft-versus-host disease (GvHD) causing donor T-cells. The company is funded by Third Rock Ventures LLC, and Atlas Venture Inc. Magenta Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Magenta Therapeutics Inc (MGTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Magenta Therapeutics Raises USD52 Million in Series C Financing 12

Magenta Therapeutics Raises USD50 Million in Series B Financing 14

Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16

Partnerships 17

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17

Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18

Magenta Therapeutics Enters into Agreement with University of Minnesota 19

Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20

Licensing Agreements 21

Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21

Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22

Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23

Equity Offering 24

Magenta Therapeutics Raises USD100 Million in IPO of Shares 24

Debt Offering 26

Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26

Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27

Magenta Therapeutics Inc-Key Competitors 28

Magenta Therapeutics Inc-Key Employees 29

Magenta Therapeutics Inc-Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Aug 09, 2018: Magenta Therapeutics reports recent operational progress and second quarter 2018 financial results 31

Corporate Communications 32

Apr 09, 2018: Magenta Therapeutics Appoints Amy Ronneberg to its Board of Directors 32

Apr 06, 2018: Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors 33

Apr 03, 2018: Magenta Therapeutics announces departure of chief operating officer Bastiano Sanna, Ph.D. 34

Feb 21, 2018: Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer 35

Oct 24, 2017: Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors 36

Legal and Regulatory 37

Sep 24, 2018: Magenta Therapeutics added to Russell 2000 and 3000 Indexes 37

Product News 38

12/11/2017: Magenta's Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase II Clinical Studies 38

Dec 09, 2017: Magenta Therapeutics' lead targeted antibody drug conjugate shows promising preclinical results for non-genotoxic conditioning for bone marrow transplant 39

05/10/2017: Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting 40

Clinical Trials 41

Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders 41

Nov 01, 2017: Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting 42

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Magenta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Magenta Therapeutics Raises USD52 Million in Series C Financing 12

Magenta Therapeutics Raises USD50 Million in Series B Financing 14

Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17

Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18

Magenta Therapeutics Enters into Agreement with University of Minnesota 19

Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20

Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21

Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22

Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23

Magenta Therapeutics Raises USD100 Million in IPO of Shares 24

Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26

Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27

Magenta Therapeutics Inc, Key Competitors 28

Magenta Therapeutics Inc, Key Employees 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Magenta Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.